ADAR1: A New Target for Immuno-oncology Therapy
- PMID: 30849393
- DOI: 10.1016/j.molcel.2019.02.021
ADAR1: A New Target for Immuno-oncology Therapy
Abstract
Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target.
Copyright © 2019 Elsevier Inc. All rights reserved.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
